JP2025507338A5 - - Google Patents

Info

Publication number
JP2025507338A5
JP2025507338A5 JP2024547150A JP2024547150A JP2025507338A5 JP 2025507338 A5 JP2025507338 A5 JP 2025507338A5 JP 2024547150 A JP2024547150 A JP 2024547150A JP 2024547150 A JP2024547150 A JP 2024547150A JP 2025507338 A5 JP2025507338 A5 JP 2025507338A5
Authority
JP
Japan
Prior art keywords
seq
sequence number
sequence
disorder
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062101 external-priority patent/WO2023154693A1/en
Publication of JP2025507338A publication Critical patent/JP2025507338A/ja
Publication of JP2025507338A5 publication Critical patent/JP2025507338A5/ja
Pending legal-status Critical Current

Links

JP2024547150A 2022-02-08 2023-02-07 Aavカプシドバリアント及びその使用 Pending JP2025507338A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307742P 2022-02-08 2022-02-08
US63/307,742 2022-02-08
US202263339574P 2022-05-09 2022-05-09
US63/339,574 2022-05-09
PCT/US2023/062101 WO2023154693A1 (en) 2022-02-08 2023-02-07 Aav capsid variants and uses thereof

Publications (2)

Publication Number Publication Date
JP2025507338A JP2025507338A (ja) 2025-03-18
JP2025507338A5 true JP2025507338A5 (cg-RX-API-DMAC7.html) 2026-02-05

Family

ID=85505478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547150A Pending JP2025507338A (ja) 2022-02-08 2023-02-07 Aavカプシドバリアント及びその使用

Country Status (11)

Country Link
US (1) US20250161485A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476241A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507338A (cg-RX-API-DMAC7.html)
KR (1) KR20240161976A (cg-RX-API-DMAC7.html)
CN (1) CN119072486A (cg-RX-API-DMAC7.html)
AU (1) AU2023217698A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249551A1 (cg-RX-API-DMAC7.html)
IL (1) IL314156A (cg-RX-API-DMAC7.html)
MX (1) MX2024009660A (cg-RX-API-DMAC7.html)
TW (1) TW202346599A (cg-RX-API-DMAC7.html)
WO (1) WO2023154693A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
EP4426716A1 (en) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025038796A1 (en) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025038805A1 (en) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025038795A1 (en) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025038800A1 (en) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to frataxin deficiency
WO2025038802A1 (en) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025038430A1 (en) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
CN117402222B (zh) * 2023-11-17 2024-03-29 广州派真生物技术有限公司 腺相关病毒突变体及其应用
KR102844372B1 (ko) * 2023-12-06 2025-08-11 주식회사 글루진테라퓨틱스 뇌 성상교세포 특이적 유전자 전달이 가능한 아데노부속바이러스 변이체와 이의 응용
US20250273289A1 (en) * 2024-02-23 2025-08-28 Tata Consultancy Services Limited Insilico method and system for designing a baseline peptide bioreceptor for sensing a biomarker for dysglycemic disorders
WO2026096603A1 (en) 2024-10-30 2026-05-07 Neurocrine Biosciences, Inc. Compositions and methods for delivering syntaxin-binding protein-1
WO2026096611A1 (en) 2024-10-30 2026-05-07 Neurocrine Biosciences, Inc. Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
WO2026096599A1 (en) 2024-10-30 2026-05-07 Neurocrine Biosciences, Inc. Compositions and methods for delivering syntaxin-binding protein-1
WO2026096600A1 (en) 2024-10-30 2026-05-07 Neurocrine Biosciences, Inc. Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
CN119552222B (zh) * 2025-01-24 2025-08-08 中国人民解放军军事科学院军事医学研究院 腺相关病毒视网膜细胞嗜性衣壳突变体及应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2640638B1 (fr) 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
ATE286138T1 (de) 1998-03-20 2005-01-15 Univ Pennsylvania Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
JP2003501067A (ja) 1999-06-02 2003-01-14 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヘルパーウイルスを要求する組み換えウイルス産生のために有用な組成物及び方法
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
WO2005001103A2 (en) 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
MX2021007600A (es) 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.
WO2021202651A1 (en) 2020-04-01 2021-10-07 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
JP2023529315A (ja) 2020-05-26 2023-07-10 シェイプ セラピューティクス インコーポレイテッド 機能的aavカプシドのハイスループット工学操作

Similar Documents

Publication Publication Date Title
JP2023525810A5 (cg-RX-API-DMAC7.html)
US20250161485A1 (en) Aav capsid variants and uses thereof
JP2022526018A5 (cg-RX-API-DMAC7.html)
JP2021534809A (ja) Aavカプシドの向性の再指向化
AU2017227803A1 (en) Therapy for frontotemporal dementia
JP2017513861A (ja) 末梢性ニューロパチー及び運動ニューロン疾患の治療方法
JP2024513949A5 (cg-RX-API-DMAC7.html)
CN121152795A (zh) 工程化aav衣壳stac-102的适合度成熟
KR20260011703A (ko) 조작된 혈액 뇌 장벽 침투성 aav 캡시드
KR20240110849A (ko) Aadc/gdnf 폴리뉴클레오티드 및 이의 파킨슨병 치료에 있어서의 용도
JP2025513066A5 (cg-RX-API-DMAC7.html)
JP2023500011A5 (cg-RX-API-DMAC7.html)
JP2021534154A5 (cg-RX-API-DMAC7.html)
WO2025038430A1 (en) Aav capsid variants and uses thereof
US20230242602A1 (en) Zinc finger protein transcription factors for repressing tau expression
JP2024523445A5 (cg-RX-API-DMAC7.html)
JP2022536338A5 (cg-RX-API-DMAC7.html)
CN113646436A (zh) 腺相关病毒对cln3多核苷酸的递送
TW202033768A (zh) 腺相關病毒對cln6聚核苷酸的遞送
JP2025516186A5 (cg-RX-API-DMAC7.html)
JP2022525848A5 (cg-RX-API-DMAC7.html)
JP2025503910A5 (cg-RX-API-DMAC7.html)
JP2023551254A5 (cg-RX-API-DMAC7.html)
JP2025512061A5 (cg-RX-API-DMAC7.html)
JP2024530050A5 (cg-RX-API-DMAC7.html)